nach oben

Erschienen in:

10.11.2016 | Original Article

Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study

verfasst von: Yves Boucher, Adeline Braud, Evelyne Dufour, Scarlette Agbo-Godeau, Vanessa Baaroun, Vianney Descroix, Marie-Thérèse Guinnepain, Marie-Noëlle Ungeheuer, Catherine Ottone, Catherine Rougeot

Erschienen in: Clinical Oral Investigations | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Idiopathic Burning mouth syndrome (iBMS) is a poorly understood affection characterized by persistent pain in the oral cavity without any clinical or biological abnormality. Opiorphin is a natural inhibitor of enkephalin-inactivating ectopeptidases, mainly produced by salivary glands, that has demonstrated analgesic properties. The objective of the present case-control study was to test the hypothesis of a decrease in opiorphin levels in iBMS patients.

Materials and methods

Twenty-one iBMS patients and 21 matched controls subjects were included between 2011 and 2013. Submandibular and sublingual salivary, blood, and urinary opiorphin levels of iBMS patients were compared to controls.

Results

Results are expressed as mean values ± SD and compared using the Wilcoxon Signed Rank test. Correlations were analyzed with Spearman coefficient. The level of significance was fixed at p < 0.05. Opiorphin levels in iBMS and controls were respectively (in ng/ml) in basal saliva: 37.8 ± 42.5 and 67.6 ± 188.9 (p = NS); stimulated saliva: 28.8 ± 25.3 and 31.1 ± 29.1 (p = NS); blood: 4.6 ± 5.4 and 1.9 ± 1.4 (p < 0.05); and urines: 68.5 ± 259.8 and 8.9 ± 6.2 (p = NS).

Clinical relevance

In conclusion, the lack of significative difference in salivary opiorphin levels between iBMS and controls does not favor a direct local role for opiorphin in the etiopathogeny of iBMS. However, higher blood opiorphin levels may reflect a systemic dysregulation in iBMS.

Trial registration

NCT02686359 https://clinicaltrials.gov/ct2/show/NCT02686359

Nur mit Berechtigung zugänglich

Merskey H (2007) The taxonomy of pain. Med Clin North Am 91(13–20):vii

Kohorst JJ, Bruce AJ, Torgerson RR, Schenck LA, Davis MD (2015) The prevalence of burning mouth syndrome: a population-based study. Br J Dermatol 172:1654–1656CrossRefPubMedPubMedCentral

Grushka M (1987) Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol 63:30–36CrossRefPubMed

Scala A, Checchi L, Montevecchi M et al (2003) Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 14:275–291CrossRefPubMed

Forssell H, Jääskeläinen S, List T et al (2014) An update on pathophysiological mechanisms related to idiopathic oro-facial pain conditions with implications for management. J Oral Rehabil 42:300–322CrossRefPubMed

Jääskeläinen SK (2012) Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 123:71–77CrossRef

Kolkka-Palomaa M, Jääskeläinen SK, Laine MA et al (2015) Pathophysiology of primary burning mouth syndrome with special focus on taste dysfunction: a review. Oral Dis 21:937–948CrossRefPubMed

Buchanan JA, Zakrzewska JM. (2016) Burning mouth syndrome. BMJ Clin. Evid. 7:1301.

Rougeot C, Messaoudi M, Hermitte V et al (2003) Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity. Proc Natl Acad Sci U S A 100:8549–8554CrossRefPubMedPubMedCentral

10.

Wisner A, Dufour E, Messaoudi M et al (2006) Human opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci 103:17979–17984CrossRefPubMedPubMedCentral

11.

bgee.uni.ch; http://bgee.unil.ch/bgee/bgee?page=gene&action=expression&gene_id=ENSG00000171199).

12.

Tóth F, Tóth G, Benyhe S et al (2012) Opiorphin highly improves the specific binding and affinity of MERF and MEGY to rat brain opioid receptors. Regul Pept 178:71–75CrossRefPubMed

13.

König M, Zimmer AM, Steiner H et al (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383:535–538CrossRefPubMed

14.

Filliol D, Ghozland S, Chluba J et al (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195–200CrossRefPubMed

15.

Tian X, Chen J, Xiong W et al (2009) Effects and underlying mechanisms of human opiorphin on colonic motility and nociception in mice. Peptides 30:1348–1354CrossRefPubMed

16.

Javelot H, Messaoudi M, Garnier S et al (2010) Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways. J Physiol Pharmacol 61:355–362PubMed

17.

Marini M, Roda LG (2000) Enkephalin-degrading enzymes and their inhibitors in human saliva. Peptides 21:125–135CrossRefPubMed

18.

Tepperman FS, Jarvis A, Hirst M (1988) Detection of enkephalin-like immunoreactive material in human saliva. Prog Neuro-Psychopharmacol Biol Psychiatry 12:285–289CrossRef

19.

Pikula DL, Harris EF, Desiderio DM et al (1992) Methionine enkephalin-like, substance P-like, and beta-endorphin-like immunoreactivity in human parotid saliva. Arch Oral Biol 37:705–709CrossRefPubMed

20.

Takeyama M, Mori K, Takayama F et al (1990) Enzyme immunoassay of a substance P-like immunoreactive substance in human plasma and saliva. Chem Pharm Bull (Tokyo) 38:3494–3496CrossRef

21.

Rougeot C, Robert F, Menz L et al (2010) Systemically active human opiorphin is a potent yet non-addictive analgesic without drug tolerance effects. J Physiol Pharmacol 61:483–490PubMed

22.

Dufour E, Villard-Saussine S, Mellon V, Leandri R, Jouannet P, Ungeheuer MN and Rougeot C. (2013) Opiorphin Secretion Pattern in Healthy Volunteers: Gender Difference and Organ Specificity. Biochem. Anal. Biochem. ; available at http://www.omicsonline.org/biochemistry-and-analytical-biochemistry- abstract.php?abstract_id = 15749 (accessed 10 october 2015).

23.

Bergdahl J, Anneroth G (1993) Burning mouth syndrome: literature review and model for research and management. J. Oral Pathol. Med. 22:433–438CrossRefPubMed

24.

Braud A, Touré B, Agbo-Godeau S et al (2013) Characteristics of pain assessed with visual analog scale and questionnaire in burning mouth syndrome patients: a pilot study. J Orofac Pain 27:235–242PubMed

25.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRefPubMed

26.

Hershkovich O, Nagler RM (2004) Biochemical analysis of saliva and taste acuity evaluation in patients with burning mouth syndrome, xerostomia and/or gustatory disturbances. Arch Oral Biol 49:515–522CrossRefPubMed

27.

de Moura SAB, de Sousa JMA, Lima DF et al (2007) Burning mouth syndrome (BMS): sialometric and sialochemical analysis and salivary protein profile. Gerodontology 24:173–176CrossRefPubMed

28.

Borelli V, Marchioli A, Di Taranto R et al (2010) Neuropeptides in saliva of subjects with burning mouth syndrome: a pilot study. Oral Dis 16:365–374CrossRefPubMed

29.

Spadari F, Venesia P, Azzi L et al (2015) Low basal salivary flow and burning mouth syndrome: new evidence in this enigmatic pathology. J Oral Pathol Med 44:229–233CrossRefPubMed

30.

Imura H, Shimada M, Yamazaki Y et al (2015) Characteristic changes of saliva and taste in burning mouth syndrome patients. J Oral Pathol Med doi. doi:10.1111/jop.12350

31.

Granot M, Nagler RM (2005) Association between regional idiopathic neuropathy and salivary involvement as the possible mechanism for oral sensory complaints. J Pain Off J Am Pain Soc 6:581–587CrossRef

32.

Rougeot C, Rosinski-Chupin I, Njamkepo E et al (1994) Selective processing of submandibular rat 1 protein at dibasic cleavage sites. Salivary and bloodstream secretion products Eur J Biochem FEBS 219:765–773CrossRef

33.

Rougeot C, Vienet R, Cardona A et al (1997) Targets for SMR1-pentapeptide suggest a link between the circulating peptide and mineral transport. Am J Phys 273:R1309–R1320

34.

Lamey P-J, Freeman R, Eddie S-A et al (2005) Vulnerability and presenting symptoms in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99:48–54CrossRefPubMed

35.

de Souza FTA, Teixeira AL, Amaral TMP et al (2012) Psychiatric disorders in burning mouth syndrome. J Psychosom Res 72:142–146CrossRefPubMed

36.

Adamo D, Schiavone V, Aria M et al (2013) Sleep disturbance in patients with burning mouth syndrome: a case-control study. J Orofac Pain 27:304–313CrossRefPubMed

37.

Lopez-Jornet P, Lucero-Berdugo M, Castillo-Felipe C et al (2015) Assessment of self-reported sleep disturbance and psychological status in patients with burning mouth syndrome. J Eur Acad Dermatol Venereol 29:1285–1290CrossRefPubMed

38.

Asmundson GJG, Katz J (2009) Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety 26:888–901CrossRefPubMed

Titel: Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study
verfasst von: Yves Boucher
Adeline Braud
Evelyne Dufour
Scarlette Agbo-Godeau
Vanessa Baaroun
Vianney Descroix
Marie-Thérèse Guinnepain
Marie-Noëlle Ungeheuer
Catherine Ottone
Catherine Rougeot
Publikationsdatum: 10.11.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Oral Investigations / Ausgabe 7/2017
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-016-1991-0

Neu im Fachgebiet Zahnmedizin

19.04.2024 | Vorhofflimmern | Nachrichten

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Opiorphin levels in fluids of burning mouth syndrome patients: a case-control study

Abstract

Objectives

Materials and methods

Results

Clinical relevance

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

Newsletter

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Clinical relevance

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Efficacy of desensitizing products containing 8% arginine and calcium carbonate for hypersensitivity relief in MIH-affected molars: an 8-week clinical study

Correlation of crevicular fluid and serum levels of retinol-binding protein 4 and leptin in chronic periodontitis and obesity

Impact of abutment material on peri-implant soft tissue color. An in vitro study

Was molar-incisor hypomineralisation (MIH) present in archeological case series?

The influence of implantoplasty on the diameter, chemical surface composition, and biocompatibility of titanium implants

Oral health status and need for oral care of care-dependent indwelling elderly: from admission to death

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

Newsletter